









Markets
/
Stocks
/
nasdaq-ccel
/

Cryo-Cell International Inc

CCEL

4.383USD

+0.045+1.04%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

35.30MMarket Cap

LossP/E TTM



Cryo-Cell International Inc

4.383

+0.045+1.04%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Cryo-Cell International Inc

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cryo-Cell International Inc's Score

Industry at a Glance

Industry Ranking

64 / 78

Overall Ranking

313 / 4616

Industry

Healthcare Providers & Services

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Hold

Current Rating

8.500

Target Price

+86.81%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Cryo-Cell International Inc Highlights

StrengthsRisks

Cryo-Cell International, Inc. is a cord blood banking company. The Company operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company stores approximately 235,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.

Growing

The company is in a growing phase, with the latest annual income totaling USD 31.99M.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Undervalued

The company’s latest PE is -77.83, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 994.95K shares, decreasing 5.00% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 7.30, which is higher than the Healthcare Providers & Services industry's average of 7.24. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 7.83M, representing a year-over-year decrease of 2.99%, while its net profit experienced a year-over-year decrease of 28.74%.

Score

Industry at a Glance

Previous score

7.30

Change



Financials

7.28

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.39

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.30

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.31

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.25

Key Metrics

Free cash flow

No Data

Cryo-Cell International Inc's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 6.10, which is lower than the Healthcare Providers & Services industry's average of 7.09. Its current P/E ratio is -77.83, which is -688.44% below the recent high of 457.97 and -263.32% above the recent low of -282.77.

Score

Industry at a Glance

Previous score

6.10

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 64/78

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

The company’s current earnings forecast score is 6.00, which is lower than the Healthcare Providers & Services industry's average of 7.56. The average price target for Cryo-Cell International Inc is 8.50, with a high of 8.50 and a low of 8.50.

Score

Industry at a Glance

Previous score

6.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Hold

Current Rating

8.500

Target Price

+86.81%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Cryo-Cell International Inc

CCEL

CVS Health Corp

CVS

HCA Healthcare Inc

HCA

Teladoc Health Inc

TDOC

Tenet Healthcare Corp

THC

Universal Health Services Inc

UHS

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 5.70, which is lower than the Healthcare Providers & Services industry's average of 7.11. Sideways: Currently, the stock price is trading between the resistance level at 4.62 and the support level at 4.23, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.51

Change

0.19

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(5)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.006

Sell

RSI(14)

44.651

Neutral

STOCH(KDJ)(9,3,3)

19.258

Sell

ATR(14)

0.140

Low Volatility

CCI(14)

-131.378

Sell

Williams %R

82.088

Oversold

TRIX(12,20)

-0.121

Sell

StochRSI(14)

31.544

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

4.442

Sell

MA10

4.449

Sell

MA20

4.461

Sell

MA50

4.550

Sell

MA100

4.712

Sell

MA200

5.470

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-05

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Portnoy (David I)

1.68M

+6.81%

Portnoy (Mark)

935.77K

Fleishman (Adam)

509.00K

Hamilton Lane Advisors, LLC

409.73K

SFI Advisors LLC

165.30K

The Vanguard Group, Inc.

Star Investors

129.81K

+9.79%

The MassMutual Trust Company, FSB

111.03K

Mikulinsky (Oleg)

104.35K

Berger (Harold D)

57.90K

Geode Capital Management, L.L.C.

45.83K

+1.33%

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 3.12, which is lower than the Healthcare Providers & Services industry's average of 5.45. The company's beta value is 0.54. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.